Fortress Historical Financial Ratios
| FBIO Stock | USD 2.12 0.13 5.78% |
Fortress Biotech is recently reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.03 or Days Sales Outstanding of 129 will help investors to properly organize and evaluate Fortress Biotech financial condition quickly.
Fortress |
About Fortress Financial Ratios Analysis
Fortress BiotechFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Fortress Biotech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Fortress financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Fortress Biotech history.
Fortress Biotech Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Fortress Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Fortress Biotech sales, a figure that is much harder to manipulate than other Fortress Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Fortress Biotech dividend as a percentage of Fortress Biotech stock price. Fortress Biotech dividend yield is a measure of Fortress Biotech stock productivity, which can be interpreted as interest rate earned on an Fortress Biotech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Fortress Biotech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Fortress Biotech current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.At this time, Fortress Biotech's Dividend Yield is very stable compared to the past year. As of the 11th of December 2024, Days Sales Outstanding is likely to grow to 129.18, while Price To Sales Ratio is likely to drop 0.27.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.043 | 0.15 | 0.36 | 0.38 | Price To Sales Ratio | 2.97 | 0.77 | 0.29 | 0.27 |
Fortress Biotech fundamentals Correlations
Click cells to compare fundamentals
Fortress Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fortress Biotech fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 3.84 | 5.01 | 2.97 | 0.77 | 0.29 | 0.27 | |
| Dividend Yield | 0.0182 | 0.0296 | 0.043 | 0.15 | 0.36 | 0.38 | |
| Ptb Ratio | 5.36 | 2.27 | 1.88 | 1.41 | 1.08 | 1.03 | |
| Days Sales Outstanding | 143.53 | 154.88 | 126.23 | 136.6 | 66.46 | 129.18 | |
| Book Value Per Share | 19.89 | 41.04 | 41.47 | 8.44 | 0.2 | 0.19 | |
| Free Cash Flow Yield | (0.74) | (0.4) | (0.65) | (3.11) | (5.58) | (5.3) | |
| Operating Cash Flow Per Share | (26.03) | (17.43) | (21.4) | (30.28) | (15.81) | (16.6) | |
| Stock Based Compensation To Revenue | 0.36 | 0.29 | 0.28 | 0.3 | 0.2 | 0.19 | |
| Capex To Depreciation | 2.02 | 1.35 | 2.41 | 0.33 | 0.0105 | 0.00998 | |
| Pb Ratio | 5.36 | 2.27 | 1.88 | 1.41 | 1.08 | 1.03 | |
| Ev To Sales | 3.25 | 1.84 | (0.39) | 0.1 | 0.38 | 0.36 | |
| Free Cash Flow Per Share | (28.61) | (18.92) | (24.4) | (30.79) | (16.81) | (17.65) | |
| Roic | (0.48) | (0.57) | (1.12) | (1.4) | (1.58) | (1.66) | |
| Inventory Turnover | 12.29 | 10.39 | 3.25 | 2.17 | 2.61 | 2.48 | |
| Net Income Per Share | (14.2) | (21.45) | (30.26) | (36.1) | (7.48) | (7.85) | |
| Days Of Inventory On Hand | 29.7 | 35.11 | 112.19 | 167.93 | 139.73 | 146.72 | |
| Payables Turnover | 0.3 | 1.28 | 0.68 | 0.54 | 0.77 | 0.73 | |
| Research And Ddevelopement To Revenue | 2.22 | 1.41 | 1.87 | 1.78 | 1.26 | 1.19 | |
| Capex To Revenue | 0.26 | 0.16 | 0.24 | 0.0403 | 7.45E-4 | 7.08E-4 | |
| Cash Per Share | 41.63 | 48.61 | 56.13 | 30.09 | 9.98 | 9.48 | |
| Pocfratio | (1.48) | (2.73) | (1.75) | (0.33) | (0.19) | (0.2) | |
| Interest Coverage | (9.35) | (9.71) | (11.69) | (14.83) | (11.95) | (12.54) | |
| Payout Ratio | (0.0279) | (0.0494) | (0.0656) | (0.0533) | (0.041) | (0.14) | |
| Capex To Operating Cash Flow | (0.0989) | (0.0856) | (0.14) | (0.017) | (4.91E-4) | (5.16E-4) | |
| Pfcf Ratio | (1.35) | (2.51) | (1.54) | (0.32) | (0.18) | (0.19) | |
| Days Payables Outstanding | 1.2K | 285.42 | 539.57 | 678.93 | 476.58 | 475.3 | |
| Income Quality | 0.76 | 0.93 | 0.81 | 0.71 | 2.11 | 2.22 | |
| Roe | (1.98) | (1.03) | (1.52) | (5.13) | (2.69) | (2.82) | |
| Ev To Operating Cash Flow | (1.25) | (1.0) | 0.23 | (0.0431) | (0.25) | (0.26) | |
| Pe Ratio | (2.71) | (2.22) | (1.24) | (0.27) | (0.4) | (0.42) | |
| Return On Tangible Assets | (0.32) | (0.6) | (0.24) | (0.33) | (0.43) | (0.8) | |
| Ev To Free Cash Flow | (0.47) | (1.14) | (0.92) | (0.0424) | (0.24) | (0.25) | |
| Earnings Yield | (0.37) | (0.45) | (0.81) | (3.65) | (2.48) | (2.36) | |
| Intangibles To Total Assets | 0.0326 | 0.0445 | 0.0317 | 0.0924 | 0.12 | 0.0846 | |
| Net Debt To E B I T D A | 0.26 | 1.64 | 1.62 | 0.27 | (0.0574) | (0.0545) | |
| Current Ratio | 2.0 | 3.43 | 5.45 | 1.8 | 1.38 | 1.31 | |
| Tangible Book Value Per Share | 17.86 | 37.99 | 39.17 | 3.85 | (2.31) | (2.19) | |
| Receivables Turnover | 2.54 | 2.36 | 2.89 | 2.67 | 5.49 | 6.02 | |
| Graham Number | 47.93 | 100.45 | 116.56 | 75.63 | 21.62 | 20.54 |
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Fortress Stock
Moving against Fortress Stock
| 0.46 | SLS | Sellas Life Sciences | PairCorr |
| 0.35 | GNFT | Genfit | PairCorr |
| 0.33 | ERNA | Eterna Therapeutics | PairCorr |
| 0.31 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (27.73) | Revenue Per Share 6.15 | Quarterly Revenue Growth (0.14) | Return On Assets (0.36) | Return On Equity (17.40) |
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.